Plexxikon

Publication List

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O'Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T. and McArthur, A. G.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
(2011) N Engl J Med. 364, 2507-2516

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., Rugo, H. S., Hwang, E. S., Jirström, K., West, B. L. and Coussens, L. M.
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
(2011) Cancer Discovery. 1, 54-67

Xing, F., Persaud, Y., Pratilas, C. A., Taylor, B. S., Janakiraman, M., She, Q. B., Gallardo, H., Liu, C., Merghoub, T., Hefter, B., Dolgalev, I., Viale, A., Heguy, A., De Stanchina, E., Cobrinik, D., Bollag, G., Wolchok, J., Houghton, A. and Solit, D. B.
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
(2011) Oncogene

Tie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., McKay, D., Bollag, G., Nolop, K., Sieber, O. M. and Desai, J.
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
(2011) Int J Cancer. 128, 2075-2084

Nucera, C., Nehs, M. A., Nagarkatti, S. S., Sadow, P. M., Mekel, M., Fischer, A. H., Lin, P. S., Bollag, G. E., Lawler, J., Hodin, R. A. and Parangi, S.
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
(2011) Oncologist. 16, 296-309

Gutmann, D. H., Stiles, C. D., Lowe, S. W., Bollag, G. E., Furnari, F. B. and Charest, A.
Report from the fifth national cancer institute mouse models of human cancers consortium nervous system tumors workshop.
(2011) Neuro Oncol. 13, 692-699

Buchholz, B., Klanke, B., Schley, G., Bollag, G., Tsai, J., Kroening, S., Yoshihara, D., Wallace, D. P., Kraenzlin, B., Gretz, N., Hirth, P., Eckardt, K. U. and Bernhardt, W. M.
The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
(2011) Nephrol Dial Transplant

Bollag, G.
Setting up a Kinase Discovery and Development Project.
(2011) Curr Top Microbiol Immunol

Zhang, C. and Bollag, G.)
Scaffold-based design of kinase inhibitors for cancer therapy.
(2010 Curr Opin Genet Dev. 20, 79-86

Plexxikon

Publication List

Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., Grippo, J. F., Schostack, K., Simcox, M. E., Heimbrook, D., Bollag, G. and Su, F.
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
(2010) Cancer Res. 70, 5518-5527

Tap, W. D., Gong, K. W., Dering, J., Tseng, Y., Ginther, C., Pauletti, G., Glaspy, J. A., Essner, R., Bollag, G., Hirth, P., Zhang, C. and Slamon, D. J.
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
(2010) Neoplasia. 12, 637-649

Salerno, P., De Falco, V., Tamburrino, A., Nappi, T. C., Vecchio, G., Schweppe, R. E., Bollag, G., Santoro, M. and Salvatore, G.
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
(2010) J Clin Endocrinol Metab. 95, 450-455

Rauen, K. A., Schoyer, L., McCormick, F., Lin, A. E., Allanson, J. E., Stevenson, D. A., Gripp, K. W., Neri, G., Carey, J. C., Legius, E., Tartaglia, M., Schubbert, S., Roberts, A. E., Gelb, B. D., Shannon, K., Gutmann, D. H., McMahon, M., Guerra, C., Fagin, J. A., Yu, B., Aoki, Y., Neel, B. G., Balmain, A., Drake, R. R., Nolan, G. P., Zenker, M., Bollag, G., Sebolt-Leopold, J., Gibbs, J. B., Silva, A. J., Patton, E. E., Viskochil, D. H., Kieran, M. W., Korf, B. R., Hagerman, R. J., Packer, R. J. and Melese, T.
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
(2010) Am J Med Genet A. 152A, 4-24

Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. and Rosen, N.
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
(2010) Nature. 464, 427-430

Lee, J. T., Li, L., Brafford, P. A., van den Eijnden, M., Halloran, M. B., Sproesser, K., Haass, N. K., Smalley, K. S., Tsai, J., Bollag, G. and Herlyn, M.
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
(2010) Pigment Cell Melanoma Res. 23, 820-827

Joseph, E. W., Pratilas, C. A., Poulikakos, P. I., Tadi, M., Wang, W., Taylor, B. S., Halilovic, E., Persaud, Y., Xing, F., Viale, A., Tsai, J., Chapman, P. B., Bollag, G., Solit, D. B. and Rosen, N.
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
(2010) Proc Natl Acad Sci U S A. 107, 14903-14908

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. and Chapman, P. B.
Inhibition of mutated, activated BRAF in metastatic melanoma.
(2010) N Engl J Med. 363, 809-819

Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., Burton, E. A., Wong, B., Tsang, G., West, B. L., Powell, B., Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K. Y., Artis, D. R., Schlessinger, J., Su, F., Higgins, B., Iyer, R., D'Andrea, K., Koehler, A., Stumm, M., Lin, P. S., Lee, R. J., Grippo, J., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., Chapman, P. B., Flaherty, K. T., Xu, X., Nathanson, K. L. and Nolop, K.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
(2010) Nature. 467, 596-599

Plexxikon

Publication List

Evans, D. G., Kalamarides, M., Hunter-Schaedle, K., Blakeley, J., Allen, J., Babovic-Vuskanovic, D., Belzberg, A., Bollag, G., Chen, R., DiTomaso, E., Golfinos, J., Harris, G., Jacob, A., Kalpana, G., Karajannis, M., Korf, B., Kurzrock, R., Law, M., McClatchey, A., Packer, R., Roehm, P., Rubenstein, A., Slattery, W., 3rd, Tonsgard, J. H., Welling, D. B., Widemann, B., Yohay, K. and Giovannini, M.
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
(2009) Clin Cancer Res. 15, 5032-5039

Artis, D. R., Lin, J. J., Zhang, C., Wang, W., Mehra, U., Perreault, M., Erbe, D., Krupka, H. I., England, B. P., Arnold, J., Plotnikov, A. N., Marimuthu, A., Nguyen, H., Will, S., Signaevsky, M., Kral, J., Cantwell, J., Settachatgull, C., Yan, D. S., Fong, D., Oh, A., Shi, S., Womack, P., Powell, B., Habets, G., West, B. L., Zhang, K. Y., Milburn, M. V., Vlasuk, G. P., Hirth, K. P., Nolop, K., Bollag, G., Ibrahim, P. N. and Tobin, J. F.
Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
(2009) Proc Natl Acad Sci U S A. 106, 262-267

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., Sproesser, K., Li, L., Smalley, K. S., Fong, D., Zhu, Y. L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., Cheung, I., Rice, J., Suzuki, Y., Luu, C., Settachatgul, C., Shellooe, R., Cantwell, J., Kim, S. H., Schlessinger, J., Zhang, K. Y., West, B. L., Powell, B., Habets, G., Zhang, C., Ibrahim, P. N., Hirth, P., Artis, D. R., Herlyn, M. and Bollag, G.
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
(2008) Proc Natl Acad Sci U S A. 105, 3041-3046

Sala, E., Mologni, L., Truffa, S., Gaetano, C., Bollag, G. E. and Gambacorti-Passerini, C.
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
(2008) Mol Cancer Res. 6, 751-759

Louvet, C., Szot, G. L., Lang, J., Lee, M. R., Martinier, N., Bollag, G., Zhu, S., Weiss, A. and Bluestone, J. A.
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
(2008) Proc Natl Acad Sci U S A. 105, 18895-18900

Shannon, K. and Bollag, G.
Sending out an SOS.
(2007) Nat Genet. 39, 8-9

Schubbert, S., Shannon, K. and Bollag, G.
Hyperactive Ras in developmental disorders and cancer.
(2007) Nat Rev Cancer. 7, 295-308

Schubbert, S., Bollag, G. and Shannon, K.
Deregulated Ras signaling in developmental disorders: new tricks for an old dog.
(2007) Curr Opin Genet Dev. 17, 15-22

Schubbert, S., Bollag, G., Lyubynska, N., Nguyen, H., Kratz, C. P., Zenker, M., Niemeyer, C. M., Molven, A. and Shannon, K.
Biochemical and functional characterization of germ line KRAS mutations.
(2007) Mol Cell Biol. 27, 7765-7770

Wang, W., Marimuthu, A., Tsai, J., Kumar, A., Krupka, H. I., Zhang, C., Powell, B., Suzuki, Y., Nguyen, H., Tabrizizad, M., Luu, C. and West, B. L.
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.
(2006) Proc Natl Acad Sci U S A. 103, 3563-3568

Plexxikon

Publication List

Schubbert, S., Zenker, M., Rowe, S. L., Boll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L. E., Nguyen, H., West, B., Zhang, K. Y., Sistermans, E., Rauch, A., Niemeyer, C. M., Shannon, K. and Kratz, C. P.
Germline KRAS mutations cause Noonan syndrome.
(2006) Nat Genet. 38, 331-336

Kratz, C. P., Schubbert, S., Bollag, G., Niemeyer, C. M., Shannon, K. M. and Zenker, M.
Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.
(2006) Cell Cycle. 5, 1607-1611

Zhang, K. Y., Ibrahim, P. N., Gillette, S. and Bollag, G.
Phosphodiesterase-4 as a potential drug target.
(2005) Expert Opin Ther Targets. 9, 1283-1305

Wang, W., Zhang, C., Marimuthu, A., Krupka, H. I., Tabrizizad, M., Shelloe, R., Mehra, U., Eng, K., Nguyen, H., Settachatgul, C., Powell, B., Milburn, M. V. and West, B. L.
The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1.
(2005) Proc Natl Acad Sci U S A. 102, 7505-7510

Smith, P. G., Wang, F., Wilkinson, K. N., Savage, K. J., Klein, U., Neuberg, D. S., Bollag, G., Shipp, M. A. and Aguiar, R. C.
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
(2005) Blood. 105, 308-316

Kumar, A., Mandiyan, V., Suzuki, Y., Zhang, C., Rice, J., Tsai, J., Artis, D. R., Ibrahim, P. and Bremer, R.
Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.
(2005) J Mol Biol. 348, 183-193

Houslay, M. D., Schafer, P. and Zhang, K. Y.
Keynote review: phosphodiesterase-4 as a therapeutic target.
(2005) Drug Discov Today. 10, 1503-1519

Hou, J., Jun, S. R., Zhang, C. and Kim, S. H.
Global mapping of the protein structure space and application in structure-based inference of protein function.
(2005) Proc Natl Acad Sci U S A. 102, 3651-3656

Card, G. L., Blasdel, L., England, B. P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim, P. N., Artis, D. R., Bollag, G., Milburn, M. V., Kim, S. H., Schlessinger, J. and Zhang, K. Y.
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
(2005) Nat Biotechnol. 23, 201-207

Zhang, K. Y., Card, G. L., Suzuki, Y., Artis, D. R., Fong, D., Gillette, S., Hsieh, D., Neiman, J., West, B. L., Zhang, C., Milburn, M. V., Kim, S. H., Schlessinger, J. and Bollag, G.
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
(2004) Mol Cell. 15, 279-286

Plexxikon

Publication List

Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P. N., Artis, D. R., Bollag, G., Milburn, M. V., Kim, S. H., Schlessinger, J. and Zhang, K. Y.
Structural basis for the activity of drugs that inhibit phosphodiesterases.
(2004) Structure. 12, 2233-2247

Zhang, K. Y. (2003)
Multidimensional histograms for density modification.
(2004) Methods Enzymol. 374, 188-203

Zhang, C. and Kim, S. H.
Overview of structural genomics: from structure to function.
(2003) Curr Opin Chem Biol. 7, 28-32

Bollag, G., Freeman, S., Lyons, J. F. and Post, L. E.
Raf pathway inhibitors in oncology.
(2003) Curr Opin Investig Drugs. 4, 1436-1441

Additional Zelboraf References

Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., Macconaill, L. E., Hahn, W. C., Meyerson, M. and Garraway, L. A.
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
(2011) J Clin Oncol. 29, 3085-3096

Vultur, A., Villanueva, J. and Herlyn, M.
Targeting BRAF in advanced melanoma: a first step toward manageable disease.
(2011) Clin Cancer Res. 17, 1658-1663

Tuma, R. S.
Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug.
(2011) J Natl Cancer Inst. 103, 170-171, 177

Solit, D. B. and Rosen, N.
Resistance to BRAF inhibition in melanomas.
(2011) N Engl J Med. 364, 772-774

Ribas, A. and Flaherty, K. T.
BRAF targeted therapy changes the treatment paradigm in melanoma.
(2011) Nat Rev Clin Oncol. 8, 426-433

Pratilas, C. A., Xing, F. and Solit, D. B.
Targeting Oncogenic BRAF in Human Cancer.
(2011) Curr Top Microbiol Immunol

Miller, F. G. and Joffe, S.
Equipoise and the dilemma of randomized clinical trials.
(2011) N Engl J Med. 364, 476-480

Mann, H.
Equipoise and the dilemma of randomized clinical trials.
(2011) N Engl J Med. 364, 2076-2077; author reply 2077

Plexxikon

Publication List

Eggermont, A. M. and Robert, C.
New drugs in melanoma: It's a whole new world.
(2011) Eur J Cancer

Chabner, B. A.
Early accelerated approval for highly targeted cancer drugs.
(2011) N Engl J Med. 364, 1087-1089

Vultur, A., Villanueva, J. and Herlyn, M.
BRAF inhibitor unveils its potential against advanced melanoma.
(2010) Cancer Cell. 18, 301-302

Solit, D. and Sawyers, C. L.
Drug discovery: How melanomas bypass new therapy.
(2010) Nature. 468, 902-903

Solit, D. and Rosen, N.
Oncogenic RAF: a brief history of time.
(2010) Pigment Cell Melanoma Res. 23, 760-762

Smalley, K. S. and Sondak, V. K.
Melanoma--an unlikely poster child for personalized cancer therapy.
(2010) N Engl J Med. 363, 876-878

Shepherd, C., Puzanov, I. and Sosman, J. A.
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
(2010) Curr Oncol Rep. 12, 146-152

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M. K., Attar, N., Sazegar, H., Chodon, T., Nelson, S. F., McArthur, G., Sosman, J. A., Ribas, A. and Lo, R. S.
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
(2010) Nature. 468, 973-977

Ledford, H.
The roots of resistance.
(2010) Nature. 468, 490

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C. and Garraway, L. A.
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
(2010) Nature. 468, 968-972

Garber, K.
Industry makes strides in melanoma.
(2010) Nat Biotechnol. 28, 763-764